Terms: = Head and neck cancer AND SDHAF2, ENSG00000167985, C11orf79, FLJ20487, 54949 AND Treatment
4 results:
1. The Changing Paradigm of head and neck Paragangliomas: What Every Otolaryngologist Needs to Know.
Cass ND; Schopper MA; Lubin JA; Fishbein L; Gubbels SP
Ann Otol Rhinol Laryngol; 2020 Nov; 129(11):1135-1143. PubMed ID: 32486832
[TBL] [Abstract] [Full Text] [Related]
2. PHEOCHROMOCYTOMA: A GENETIC and DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract] [Full Text] [Related]
3. head and neck paragangliomas: clinical and molecular genetic classification.
Offergeld C; Brase C; Yaremchuk S; Mader I; Rischke HC; Gläsker S; Schmid KW; Wiech T; Preuss SF; Suárez C; Kopeć T; Patocs A; Wohllk N; Malekpour M; Boedeker CC; Neumann HP
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):19-28. PubMed ID: 22584701
[TBL] [Abstract] [Full Text] [Related]
4. Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in individuals with neck or mediastinal paraganglioma (PGL).
Zovato S; Kumanova A; Demattè S; Sansovini M; Bodei L; Di Sarra D; Casagranda E; Severi S; Ambrosetti A; Schiavi F; Opocher G; Paganelli G
Horm Metab Res; 2012 May; 44(5):411-4. PubMed ID: 22566197
[TBL] [Abstract] [Full Text] [Related]
